Modeling Melanoma Resistance: Using Tumour Models to Validate JJP-1008 mAb Targeting CD160 & CD272
Time: 12:45 pm
day: Conference Day One
Details:
- Identifying CD160 and CD272 as key contributors to melanoma resistance in preclinical models, highlighting their clinical relevance in tumour immune evasion
- Demonstrating JJP-1008 as the first selective CD270 inhibitory signal-blocking IgG4 mAb, showing promising potential in overcoming melanoma resistance in model systems
- Showing through preclinical studies that JJP-1008 induces the shedding of LIGHT (CD258), offering new insights into the HVEM pathway and its potential for enhancing immunotherapy efficacy in melanoma models
